Our focus: Contemporary healthcare challenges
Growing patient empowerment, downward price pressure and relentless competition has squeezed the traditional pharma business model more than ever. But staying competitive in this fast-evolving marketplace is only part of the story.
Tackling contemporary healthcare challenges requires active collaboration between stakeholders from across the entire healthcare landscape. At GenCaps, our focus is on developing innovative OSD formulations that help our partners maximise the value of their portfolios while meeting their environmental and social commitments of tomorrow.
Drug Delivery Systems (DDS)
DDS limitations can deprive patients of a drug’s full therapeutic potential (e.g. low bioavailability) and prevent pharmaceutical companies from establishing valuable elements of product differentiation. GenCaps’ next generation OSD formulation technology offers our partners the potential to overcome DDS limitations while creating competitive edge.
Product Lifecycle Management
As regulators continue to encourage competition in the marketplace, pharmaceutical companies face significant revenue challenges from various angles - most notably in the form of generic entrants. With Product Lifecycle Management becoming increasingly critical, GenCaps’ technology offers our partners - be they developing novel, branded generic or pure generic products - the potential to defend their market share and grow their revenues with new or enhanced formulations that enjoy competitive cost profiles and enduring, patient-focused differentiation.
Access & Affordability
Healthcare costs are a burden on both patients and public healthcare systems alike, and there is an ongoing imperative to make drugs more accessible and affordable to all those in need. GenCaps’ next generation OSD formulation technology offers our partners new ways to respond to downward price pressure by significantly reducing their cost of goods sold, while increasing supply chain flexibility thanks to a highly integrated and scaleable continuous manufacturing system. A compact GMP production footprint offers further potential for decentralized or portable production solutions.
Drug Adherence
In a 2018 report the OECD estimated that in Europe alone poor drug adherence contributed to nearly 200,000 premature deaths annually and cost governments EUR 125 billion in avoidable hospitalization and other healthcare costs. While poor drug adherence remains a complex issue, by improving user experience (e.g. ‘swallowability’), providing a wider choice of dosage strengths and offering the potential for multiple APIs (potentially relevant for patients with a high OSD daily intake), our technology offers new alternatives to tackling the issue of poor drug adherence. For pharmaceutical firms, the rise of value-based agreements - where patient outcomes are critical - makes optimising drug adherence an imperative.
Innovative OSD formulations and cost reduction in one
GenCaps’ differentiated technology simultaneously offers patient-focused format differentiation and substantial cost of goods reduction to help maximise the value of your OSD portfolio.
Patient-focused, advanced formulations
Innovative, monolithic dose unit
Versatile, advanced OSD formulations
High drug loads
Efficient Continuous Manufacturing Technology (CMT)
Unique, two-step continuous process (batch mode optional)
Significant COGS reduction
‘Smart’ Pharma 4.0 production tech
Next Generation Technology
Combining next generation OSD formulation solutions with the step-change of continuous manufacturing, GenCap’s pioneering technology brings you a step closer to Pharma 4.0.
Dose Unit Engineering
Next generation OSD formulation technology combining a unique composition with a tailored drug delivery system.
Innovative formulation
High API-to-volume ratio permits a reduced-format dosage size and fixed dose combinations (e.g. two APIs)
DDS options include immediate release, modified release, combined immediate/modified release and ‘food effect’
Continuous Manufacturing
Unique, two-step continuous process
Significant cost of goods reduction thanks to a reduced total production time for high volumes, lower production input needs and overhead efficiencies
‘Semi-continuous’ mode available to facilitate integration into a batch manufacturing context, evolving later to ‘fully-continuous’ mode
Supply Chain Agility
‘Smart’ production technology seamlessly integrates the continuous manufacturing production capability with your supply chain to offer increased flexibility, speed and agility.
Rapid process development and process changeover
Improved response capacity against changing demand patterns
A compact GMP production footprint offers the potential for decentralized or portable production
Our Approach
At GenCaps we leverage our unique know-how and differentiated technology by working with a network of highly skilled experts to help you achieve the highest standards of design, quality, manufacturing and regulatory compliance. Additionally, we work with recognised partners in the drug product manufacturing industry covering the full scale of development from clinical to commercial.
Target selection
Our work starts by identifying high-potential opportunities within the OSD market based on composition suitability, product life cycle and competition analysis
Following preliminary assessment of a drug product’s profile, we can proceed with drug substance data checks and prototyping to ensure a strong alignment with GenCaps’ approach and technology
Holistic design
We take a patient-centric yet holistic solution design approach that goes beyond formulating a drug product for a given indication but that considers how value can be maximised for stakeholders along the entire value chain, from producer to patient
Our formulation expertise enables not only the development of bespoke formulations but also the potential for IP creation that can help underpin the value creation process
Flexible solution delivery
Working with our ecosystem of business partners, we offer flexibility in solution delivery, from initial portfolio screening projects through to full drug product development and manufacturing
Our flexible approach opens up different ways in which our partners can access and leverage our solutions for maximum value, for example, via strategic development partnerships, licencing agreements or IP sale
Contact Us
To find out more about how we can work together to help maximise the value of your OSD portfolio contact us today at info@gencaps.eu